This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
EIF4G2 · Western blot design guide
EIF4G2 Western Blot Planning Guide
Plan a EIF4G2 Western blot around the catalog-observed 102.4 kDa band, image-backed A03888-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
EIF4G2 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 102.4 kDa observed | |
| Observed band | 102.4 kDa observed | |
| Gel | 8-10% | |
| Positive control | Colon | |
| Negative control | Use knockout/knockdown or orthogonal negative |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 102.4 kDa |
| ⓘ | Localization | Not reported |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated EIF4G2 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Appendix |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A03888-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected EIF4G2 Western Blot Band Size?
Use the product-observed 102.4 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 102.4 kDa | Matches the authoritative product WB observation. |
| 102.4 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected EIF4G2 appearancePlan around 102.4 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 102.4 kDa; use this as the primary experimental expectation. |
| Calculated mass | 102.4 kDa from UniProt P78344; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A03888-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 102.4 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing EIF4G2 band
A03888-2 · EIF4G2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for EIF4G2 Western blot
🧪Use Colon as the first positive-control candidate and retain an orthogonal negative control.
Positive control: Colon (High)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for EIF4G2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Colon | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | High | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Heart muscle | Reported tissue cells | Low | Protein (HPA) | HPA → |
| Oral mucosa | Reported tissue cells | Low | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|
Section 3
Advanced EIF4G2 Western Blot Tips
Deeper troubleshooting and optimisation questions for EIF4G2, answered from its protein features.
Which band should guide the blot?
Use 102.4 kDa, the observation attached to the authoritative A03888-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 102.4 kDa expectation.
Which positive control should I start with?
Start with Colon, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use a target knockdown/knockout control when no HPA Not detected tissue is available.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for EIF4G2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A03888-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
EIF4G2 Western Blot Reagents
Human/Mouse/Rat-reactive EIF4G2 Western blot reagents with authoritative product imagery.
Real WB data
Anti-P97/DAP5/EIF4G2 Antibody Picoband®
Cat # A03888-2
Real WB data
Anti-P97/DAP5/EIF4G2 Antibody Picoband®
Cat # A03888-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P78344
- Human Protein Atlas — EIF4G2
- A03888-2 product record
- PMC10860299 — MicroRNA-877-5p promotes osteoblast differentiation by targeting EIF4G2 expression (Journal of orthopaedic surgery and research, 2024)
- PMC7852102 — MiR-144-3p-mediated dysregulation of EIF4G2 contributes to the development of hepatocellular carcinoma through the ERK pathway (Journal of experimental & clinical cancer research : CR, 2021)
- PMC10761619 — Circ_0020123 promotes non-small cell lung cancer progression via miR-146a-5p mediated regulation of EIF4G2 expression (Thoracic cancer, 2024)